Fibrate Rx Works in Cholangiopathic Itch

Treatment with bezafibrate proved superior to placebo in a small randomized trial for short-term relief of moderate to severe cholestasis-associated pruritus in patients with fibrosing cholangiopathies.

The primary endpoint of a more than 50% reduction in severe or moderate pruritus at 21 days was achieved by 45% of patients in the arm given the lipid-lowering drug bezafibrate versus 11% in those receiving placebo (P=0.003), according to Ulrich Beuers, MD, of the Tytgat Institute for Liver and Intestinal Research at Amsterdam University Medical Center in the Netherlands, and colleagues.

As reported in Gastroenterology, for secondary endpoints, bezafibrate reduced the intensity of both morning (P=0.01) and evening (P=0.007) pruritus versus placebo on a visual analog scale (VAS) and also improved scores (P=0.002) on a validated itch scale questionnaire of five dimensions (degree, duration, direction, disability, and distribution).

The researchers explained that in patients with

Read More